In a Bloomberg Law article, life sciences regulatory & compliance partner Joshua Oyster discussed the recent Fifth Circuit federal appeals court ruling that abortion pill mifepristone will remain available to patients but with restrictions. However, the decision will remain on hold pending an expected review by the U.S. Supreme Court.
Joshua notes that it is unclear how the manufacturers of the brand-name and generic versions of mifepristone would update product labeling, as well as safety materials and processes, to follow the court’s order.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.